Molecular classification of multiple myeloma: A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7296-7306

  Agnelli, Luca ^a   Bicciato, Silvia ^a   Mattioli, Michela ^a   Fabris, Sonia ^a   Infini, Daniela ^a   Verdelli, Donata ^a   Baldini, Luca ^a   Morabito, Fortunato ^a   Callea, Vincenzo ^a   Lombardi, Luigia ^a   Neri, Antonino ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN D1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CCND1 GENE; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCUS; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; MARKER GENE; MOLECULAR GENETICS; MOLECULAR IMPRINTING; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; CLASSIFICATION; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 33644680752     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.3870     Document Type: Article

References (43)

1. Seidl S, Kaufmann H, Drach J: New insights into the pathophysiology of multiple myeloma. Lancet Oncol 4:557-564, 2003
2. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558, 2004
3. Chesi M, Bergsagel PL, Brents LA, et al: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674-681, 1996
4. Ronchetti D, Finelli P, Richelda R, et al: Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 93:1330-1337, 1999
5. Chesi M, Nardini E, Brents LA, et al: Frequent translocation t(4:14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16:260-264, 1997
6. Richelda R, Ronchetti D, Baldini L, et al: A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90:4062-4070, 1997
7. Chesi M, Nardini E, Lim RS, et al: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025-3034, 1998
8. Shaughnessy J Jr, Gabrea A, Qi Y, et al: Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98:217-223, 2001
9. Chesi M, Bergsagel PL, Shonukan OO, et al: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91:4457-4463, 1998
10. Hanamura I, Iida S, Akano Y, et al: Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res 92:638-644, 2001
11. Malumbres M, Barbacid M: To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1:222-231, 2001
12. Pruneri G, Fabris S, Baldini L, et al: Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 156:1505-1513, 2000
13. Specht K, Haralambieva E, Bink K, et al: Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104:1120-1126, 2004
14. Hurt EM, Wiestner A, Rosenwald A, et al: Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5:191-199, 2004
15. Hideshima T, Bergsagel PL, Kuehl WM, et al: Advances in biology of multiple myeloma: Clinical applications. Blood 104:607-618, 2004
16. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757, 2002
17. Tian E, Zhan F, Walker R, et al: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494, 2003
18. Fabris S, Agnelli L, Mattioli M, et al: Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer 42:117-127, 2005
19. Mattioli M, Agnelli L, Fabris S, et al: Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24:2461-2473, 2005
20. Durie BG, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854, 1975
21. Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264, 2003
22. Tibshirani R, Hastie T, Narasimhan B, et al: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567-6572, 2002
23. Eisen MB, Spellman PT, Brown PO, et al: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-14868, 1998
24. Schadt EE, Li C, Ellis B, et al: Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 37:120-125, 2001
25. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6:986-994, 1996
26. Elnenaei MO, Hamoudi RA, Swansbury J, et al: Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 36:99-106, 2003
27. Robbiani DF, Chesi M, Bergsagel PL: Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 351:197-198, 2004
28. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005
29. Bergsagel PL, Kuehl WM: Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96-104, 2003
30. Rosenwald IB: The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 23:3230-3247, 2004
31. Donze O, Jagus R, Koromilas AE, et al: Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J 14:3828-3834, 1995
32. Mayeur GL, Hershey JW: Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e). FEBS Lett 514:49-54, 2002
33. Morley SJ: The regulation of eIF4F during cell growth and cell death. Prog Mol Subcell Biol 27:1-37, 2001
34. Thornton S, Anand N, Purcell D, et al: Not just for housekeeping: Protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 81:536-548, 2003
35. Guttridge DC, Albanese C, Reuther JY, et al: NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785-5799, 1999
36. Hinz M, Krappmann D, Eichten A, et al: NF-kappaB function in growth control: Regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690-2698, 1999
37. Welsh JB, Zarrinkar PP, Sapinoso LM, et al: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98:1176-1181, 2001
38. Durig J, Nuckel H, Huttmann A, et al: Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. Blood 101:2748-2755, 2003
39. Soverini S, Cavo M, Cellini C, et al: Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 102:1588-1594, 2003
40. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101:4569-4575, 2003
41. Collins T, Stone JR, Williams AJ: All in the family: The BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 21:3609-3615, 2001
42. Polo JM, Dell'oso T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329-1335, 2004
43. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85:2870-2876, 1995